본문 바로가기 대메뉴 바로가기

Infectious Diseases Therapeutic Research Center
Head
  • NameChang Soo Yun
  • Office+82-42-860-7315
  • E-mailcsyun@krict.re.kr
Chang Soo Yun

Major research fields

Development of innovative technology for controlling high-risk viruses

  • Development of therapeutics for chronic hepatitis B virus
    • First-in-class target (HBx-DDB1) inhibitor efficacy development platform
  • Synthesis of effective compounds
    • Discovery of hit compounds by evaluating the compound library including more than 1500 compounds through the HTS system independently built by KRICT
    • In silico drug design, in silico virtual screening, and derivation of effective materials
  • Picornavirus therapeutics
    • Identification and verification of First-in-Class Target Mechanism
      • Derivation of effective materials by screening 10,000 compounds in Korea Chemical Bank
      • Time-of-addition evaluation to analyze the time when an effective materials starts to inhibit a virus
      • Verification of site of action by inducing tolerance of effective materials
      • Research on mutations
      • Efficacy study using animal models
    • Technology for therapeutics optimization through pharmaceutical and chemical synthesis

Development of innovative technology for treating high-risk bacteria

  • Research on suitable targets for developing antibiotics against high-risk Gram negative bacteria
  • Research on LpxC inhibition targets
  • Synthesis of effective LpxC inhibition compounds of new structures and verification of their efficacy
  • Screening of new metal binding motif through virtual screening
  • Structural optimization through molecular modeling
  • Establishment of system for measuring pharmacological activity against Gram negative bacteria and verifying LpxC target specificity
  • Establishment of in-house drug efficacy evaluation system
  • Protein purification and substrate synthesis for enzymatic assays
  • Development of Gram negative bacteria HTS platform design and imaging
  • Phase-contrast imaging-based antibiotics sensitivity test (rapid AST) and analysis of cell count
  • Dark field image-based analysis of shape and behavior of single bacterial cells by antibiotic effect

Development of new antiviral clinical candidates for effectively treating COVID-19

  • Synthesis of derivatives of effective materials for inhibiting COVID-19 infection; compound structure optimization through cell-level efficacy and toxicity evaluation; and mechanism study based on in silico modeling
  • Establishment of infection animal model, evaluation of in vivo antiviral efficacy using the model, and study of drug tolerance
  • Development of bulk synthesis method and preclinical study including in vivo pharmacokinetics and toxicity evaluation